International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective.

about

Conducting non-commercial international clinical trials: the ICR-CTSU experience.A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?

P2860

Q42364730-A40B54C5-E502-4939-A904-D33C8A2F6617 Q47160419-C186B0D1-94E8-4B65-9459-3F649F49BB4B

P2860

International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective.

Item

http://www.wikidata.org/entity/Q36863184

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

International clinical trials ...... traints-the EORTC perspective.

@en

type

Item

label

International clinical trials ...... traints-the EORTC perspective.

@en

prefLabel

International clinical trials ...... traints-the EORTC perspective.

@en

P1476

International clinical trials ...... straints-the EORTC perspective

@en

P2093

Anastassia Negrouk

http://www.w3.org/2001/XMLSchema#string

Denis Lacombe

http://www.w3.org/2001/XMLSchema#string

Francoise Meunier

http://www.w3.org/2001/XMLSchema#string

Sandrine Marreaud

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.

Public-private partnerships need honest brokering.

Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

The burden of rare cancers in Europe.

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.

Academia-industry partnerships: are we ready for new models of partnership?: the point of view of the EORTC, an academic clinical cancer research organisation.

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

How much would you give to save a dying bird? Patient advocacy and biomedical research.

P304

321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2013.321

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emad Shash

Vassilis Golfinopoulos

P577

2013-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236959436

http://www.w3.org/2001/XMLSchema#string

P698

23717342

http://www.w3.org/2001/XMLSchema#string

P932

3660157

http://www.w3.org/2001/XMLSchema#string

International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective.

about

P2860

P2860

International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932